BioCentury | Jun 30, 2014
Company News

Senesco management update

...N.J. Business: Cancer, Autoimmune, Agbio/Environmental Hired: Ronald Martell as CEO, formerly president and CEO of NeurogesX Inc....
BioCentury | Oct 31, 2013
Targets & Mechanisms

KCC2 escape from neuropathic pain

...Pharmaceutical Industries Ltd. 's Effentora , a m-opioid receptor ( OPRM1 ; MOR ) agonist; NeurogesX Inc....
...City, Quebec, Canada Universite Laval , Quebec City, Quebec, Canada Naurex Inc. , Evanston, Ill. NeurogesX Inc....
BioCentury | Jul 15, 2013
Company News

Acorda, NeurogesX deal

...neuropathic pain management products - Qutenza capsaicin and NP-1998 (formerly NGX-1998 ) - from NeurogesX. NeurogesX...
...net sales of NP-1998 in Acorda's territories reach $100 million in the first 12 months. NeurogesX...
...Qutenza is approved in the U.S. to manage neuropathic pain associated with post-herpetic neuralgia (PHN). NeurogesX...
BioCentury | Mar 18, 2013
Clinical News

Qutenza capsaicin regulatory update

...manage neuropathic pain associated with post-herpetic neuralgia (PHN). Astellas has rights to commercialize Qutenza from NeurogesX...
...European countries, as well as the Middle East and Africa (see BioCentury, June 29, 2009). NeurogesX Inc....
BioCentury | Mar 18, 2013
Company News

NovaBay management update

...Infectious Hired: Keith Bley as SVP of product development, formerly SVP of nonclinical R&D at NeurogesX Inc....
BioCentury | Jan 10, 2013
Distillery Therapeutics

Indication: Musculoskeletal disease

...loss and decreases in fiber length. Next steps could include identifying a muscle-specific TRPV1 activator. NeurogesX Inc....
...Qutenza, a dermal patch containing capsaicin, to manage neuropathic pain associated with postherpetic neuralgia (PHN). NeurogesX's...
BioCentury | Aug 13, 2012
Clinical News

Qutenza capsaicin update

...manage neuropathic pain associated with post-herpetic neuralgia (PHN). Astellas has rights to commercialize Qutenza from NeurogesX...
...Africa (see BioCentury, June 29, 2009). Pfizer Inc. (NYSE:PFE, New York, N.Y.) markets Lyrica pregabalin. NeurogesX Inc....
BioCentury | Jul 9, 2012
Financial News

NeurogesX financial update

...exchange's listing requirements. The company is now listed on the OTC Bulletin Board under "NGSX." NeurogesX Inc....
BioCentury | May 7, 2012
Strategy

Jazz's big band sound

...of R&D and CMO. He was formerly EVP of R&D and CMO of neurology company NeurogesX Inc....
...Boulogne-Billancourt, France Jazz Pharmaceuticals plc (NASDAQ:JAZZ), Dublin, Ireland Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. NeurogesX Inc....
BioCentury | Apr 30, 2012
Financial News

NeurogesX financial update

...$50 million market value requirement for continued listing. The company intends to request a hearing. NeurogesX Inc....
Items per page:
1 - 10 of 177
BioCentury | Jun 30, 2014
Company News

Senesco management update

...N.J. Business: Cancer, Autoimmune, Agbio/Environmental Hired: Ronald Martell as CEO, formerly president and CEO of NeurogesX Inc....
BioCentury | Oct 31, 2013
Targets & Mechanisms

KCC2 escape from neuropathic pain

...Pharmaceutical Industries Ltd. 's Effentora , a m-opioid receptor ( OPRM1 ; MOR ) agonist; NeurogesX Inc....
...City, Quebec, Canada Universite Laval , Quebec City, Quebec, Canada Naurex Inc. , Evanston, Ill. NeurogesX Inc....
BioCentury | Jul 15, 2013
Company News

Acorda, NeurogesX deal

...neuropathic pain management products - Qutenza capsaicin and NP-1998 (formerly NGX-1998 ) - from NeurogesX. NeurogesX...
...net sales of NP-1998 in Acorda's territories reach $100 million in the first 12 months. NeurogesX...
...Qutenza is approved in the U.S. to manage neuropathic pain associated with post-herpetic neuralgia (PHN). NeurogesX...
BioCentury | Mar 18, 2013
Clinical News

Qutenza capsaicin regulatory update

...manage neuropathic pain associated with post-herpetic neuralgia (PHN). Astellas has rights to commercialize Qutenza from NeurogesX...
...European countries, as well as the Middle East and Africa (see BioCentury, June 29, 2009). NeurogesX Inc....
BioCentury | Mar 18, 2013
Company News

NovaBay management update

...Infectious Hired: Keith Bley as SVP of product development, formerly SVP of nonclinical R&D at NeurogesX Inc....
BioCentury | Jan 10, 2013
Distillery Therapeutics

Indication: Musculoskeletal disease

...loss and decreases in fiber length. Next steps could include identifying a muscle-specific TRPV1 activator. NeurogesX Inc....
...Qutenza, a dermal patch containing capsaicin, to manage neuropathic pain associated with postherpetic neuralgia (PHN). NeurogesX's...
BioCentury | Aug 13, 2012
Clinical News

Qutenza capsaicin update

...manage neuropathic pain associated with post-herpetic neuralgia (PHN). Astellas has rights to commercialize Qutenza from NeurogesX...
...Africa (see BioCentury, June 29, 2009). Pfizer Inc. (NYSE:PFE, New York, N.Y.) markets Lyrica pregabalin. NeurogesX Inc....
BioCentury | Jul 9, 2012
Financial News

NeurogesX financial update

...exchange's listing requirements. The company is now listed on the OTC Bulletin Board under "NGSX." NeurogesX Inc....
BioCentury | May 7, 2012
Strategy

Jazz's big band sound

...of R&D and CMO. He was formerly EVP of R&D and CMO of neurology company NeurogesX Inc....
...Boulogne-Billancourt, France Jazz Pharmaceuticals plc (NASDAQ:JAZZ), Dublin, Ireland Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. NeurogesX Inc....
BioCentury | Apr 30, 2012
Financial News

NeurogesX financial update

...$50 million market value requirement for continued listing. The company intends to request a hearing. NeurogesX Inc....
Items per page:
1 - 10 of 177